Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
TPG Asia was earlier reported to be preparing a full divestment of its stake, estimated at about 3.07 crore shares or 14.72% of Sai Life's equity capital. The deal is seen as a clean-up trade marking a complete exit for the investor, which has backed the Hyderabad-based firm for several years.
Hyderabad-based Sai Life Sciences is a Contract Research, Development and Manufacturing Organization (CRDMO) that works with pharmaceutical and biotechnology companies in drug discovery, development and commercialization. The company provides services across medicinal chemistry, process development, clinical and commercial manufacturing, and technology platforms.
On a consolidated basis, Sai Life Sciences reported net profit of Rs 60.46 crore in Q1 June 2025 as against net loss of Rs 13.50 crore in Q1 June 2024. Net sales rose 77.47% year-on-year to Rs 496.42 crore in Q1 June 2025.
Powered by Capital Market - Live News